A laboratory-based study of COVID-19 in Casablanca, Morocco.
COVID-19
RT-PCR
SARS-CoV-2
laboratory test
risk factors
Journal
Journal of public health in Africa
ISSN: 2038-9922
Titre abrégé: J Public Health Afr
Pays: Italy
ID NLM: 101586943
Informations de publication
Date de publication:
31 Dec 2021
31 Dec 2021
Historique:
received:
03
06
2021
accepted:
30
09
2021
entrez:
7
2
2022
pubmed:
8
2
2022
medline:
8
2
2022
Statut:
epublish
Résumé
Given the spread of coronavirus disease 2019 (COVID-19) and its impact on human health, laboratory confirmation of diagnosis is essential. This study examined the contribution of laboratory diagnosis to the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the diagnosis of COVID-19, taking into account patient risk of exposure to SARS-CoV-2, clinical symptoms and comorbidities. A cross-sectional, laboratory-based study was carried out from 1 April 2020 to 30 April 2020 at the National Reference Laboratory in Morocco using nasopharyngeal samples from patients admitted to the Cheikh Khalifa International University Hospital or other hospitals in Casablanca. A one-step reverse transcription real-time polymerase chain reaction (RT-PCR) was used to detect the presence of the SARS-CoV-2 genome. A national epidemiological investigation form was used to analyze patient exposure risk, clinical symptoms and comorbidities. A total of 793 samples from 375 patients were analyzed and 1150 RT-PCR tests were conducted; 116 patients (30.93%) were COVID-19 positive. Travel to a risk zone, contact with a confirmed COVID-19 case and contact with a person who had been in a risk zone were significantly associated with being positive for COVID-19. Fever and cough were the main symptoms; 7.76 % of positive patients were asymptomatic. This is the first laboratory-based study in Morocco for the diagnosis of COVID-19. Laboratory diagnosis of COVID-19 by RTPCR associated with knowledge of exposure risk factors and clinical symptoms and comorbidities remains essential for clinicians for early, appropriate medical management COVID-19 patients.
Identifiants
pubmed: 35126890
doi: 10.4081/jphia.2021.1458
pmc: PMC8791017
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1458Informations de copyright
©Copyright: the Author(s).
Déclaration de conflit d'intérêts
Conflict of interest: The authors declare conflicts of interest.
Références
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
J Med Virol. 2020 Sep;92(9):1518-1524
pubmed: 32104917
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Influenza Other Respir Viruses. 2020 Jul;14(4):474-475
pubmed: 32246886
Euro Surveill. 2020 Mar;25(9):
pubmed: 32156330
Infect Genet Evol. 2020 Apr;79:104211
pubmed: 32007627
Am J Clin Pathol. 2020 Mar 9;153(4):420-421
pubmed: 32053148
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Arch Acad Emerg Med. 2020 Mar 24;8(1):e35
pubmed: 32232218
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Virol J. 2017 Nov 22;14(1):230
pubmed: 29166910
Int J Infect Dis. 2020 May;94:44-48
pubmed: 32171952